Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Pennsylvania › Lancaster
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Lancaster, PA keessatti
Qorannoo 7 Kansara Qara'a Non-Small Cell f Lancaster fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Namoota walitti qabaa jiraSadarkaa 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Namoota walitti qabaa jiraSadarkaa 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Namoota walitti qabaa jiraSadarkaa 3
- Lancaster General Hospital, Lancaster
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Namoota walitti qabaa jiraSadarkaa 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Pan-tumor MRD Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lancaster General Hospital (UPenn), Lancaster
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Namoota walitti qabaa jiraSadarkaa 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Lancaster
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Lancaster keessatti
- Dhibee Onneessaa fi DhiigaQorannoo 5
- Cufama OnneeQorannoo 5
- Saree OljooQorannoo 4
- Kansarii ProstateQorannoo 4
- Kansara MetastatikiiQorannoo 4
- Dhibee QaraQorannoo 3
- AmblyopiaQorannoo 3
- Dhukkuboota OnneeQorannoo 3
- Dukkana BladderQorannoo 3
- Kansara Baadii Harkaa Non-Muscle InvasiveQorannoo 3
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.